Selected Grants
Blood and Marrow Transplant Clinical Trials Network
Clinical TrialPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2001 - 2031Deciphera DCC-3014-02-001: A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
Clinical TrialPrincipal Investigator · Awarded by Deciphera Pharmaceuticals, LLC · 2025 - 2030A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2030A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma (ALPHA3)
Clinical TrialPrincipal Investigator · Awarded by Allogene Therapeutics, Inc. · 2024 - 2029Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 1975 - 2026ALVR106 in Treatment of High-Risk Patients with Respiratory Viral Infections After HSCT
Clinical TrialPrincipal Investigator · Awarded by Allovir, Inc. · 2021 - 2026Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
ResearchCo Investigator · Awarded by National Institutes of Health · 2015 - 2026A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2021 - 2026Prebiotics to Optimize the Microbiota and Improve Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation
ResearchPrincipal Investigator · Awarded by The University of Kansas Medical Center Research Institute, Inc · 2024 - 2025A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) BMT CTN Protocol #2002
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2022 - 2025An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients with Hematological Malignancies
Clinical TrialPrincipal Investigator · Awarded by Gamida Cell Ltd · 2020 - 2025A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2019 - 2025A Phase 2/3, Multicenter, randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of Alpha-! Antitrypsin for the Prevention of GVHD
Clinical TrialPrincipal Investigator · Awarded by CSL Behring LLC · 2019 - 2025CTN1705- Same Day Processing and Storage of Stool Samples for Stool AAT Concentrations, Microbiome and Metabolome studies
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2021 - 2024BMT CTN 1705 ¿ HR aGVHD AAT
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2019 - 2024C10162: Duke University-BMT CTN 1704 protocol study (CHARM)
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2019 - 2024FH8771_Single Arm
Clinical TrialPrincipal Investigator · Awarded by Fred Hutchinson Cancer Research Center · 2020 - 2024A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft Versus Host Disease
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2019 - 2024A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phae III trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3-ITD AML BMT CTN Protocol 1506
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Inc. · 2017 - 2023A Multicenter, Randomized, Phase III Registratoin Trial of Transplantation of NiCord, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for patients with Hematological Malignancies
Clinical TrialPrincipal Investigator · Awarded by Gamida Cell Ltd · 2016 - 2023BMT CTN 2002 CSPR
Clinical TrialPrincipal Investigator · Awarded by Xenikos BV · 2022 - 2023A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Clinical TrialPrincipal Investigator · Awarded by Washington University in St. Louis · 2017 - 2022Study Agreement #816977 Related to BMT CTN 1703/1801 Study
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2019 - 2021A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (GMT CTN Protocol 1501
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2016 - 2021A phase III Randomized Open-Label Multi-Center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogenic stem cell transplantation
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2017 - 2019Prospective, Phase I/II, randomized clinical study to compare BEGEDINA versus "conventional treatment" for treating steroid resistant acute GvHD.
Clinical TrialPrincipal Investigator · Awarded by Adienne SA · 2015 - 2019Phase III RECRUIT Study CTN 1505
Clinical TrialPrincipal Investigator · Awarded by University of Texas Health Science Center at Houston · 2015 - 2017External Relationships
- Gamida-Cell, Ltd.
- MJH Life Sciences
- OncLive
- PSI Pharma Support American Inc
- Vor Biopharma
- incyte
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.